vs
Amphastar Pharmaceuticals, Inc.（AMPH）与MARCUS CORP（MCS）财务数据对比。点击上方公司名可切换其他公司
MARCUS CORP的季度营收约是Amphastar Pharmaceuticals, Inc.的1.1倍（$193.5M vs $183.1M），MARCUS CORP同比增速更快（2.8% vs -1.8%），MARCUS CORP自由现金流更多（$26.4M vs $24.6M），过去两年MARCUS CORP的营收复合增速更高（18.2% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
马库斯公司是一家美国企业，主营商业地产领域相关服务，业务覆盖美国与加拿大，提供商业地产经纪、按揭经纪、行业研究以及咨询服务，首创了由单一经纪公司独家代理房源挂牌的行业模式，目前在美加两国设有超过80家办公室，拥有员工超1800名。
AMPH vs MCS — 直观对比
营收规模更大
MCS
是对方的1.1倍
$183.1M
营收增速更快
MCS
高出4.6%
-1.8%
自由现金流更多
MCS
多$1.8M
$24.6M
两年增速更快
MCS
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $193.5M |
| 净利润 | $24.4M | — |
| 毛利率 | 46.8% | — |
| 营业利润率 | 19.4% | 0.9% |
| 净利率 | 13.3% | — |
| 营收同比 | -1.8% | 2.8% |
| 净利润同比 | -35.7% | — |
| 每股收益（稀释后） | $0.51 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHMCS
| Q4 25 | $183.1M | $193.5M | ||
| Q3 25 | $191.8M | $210.2M | ||
| Q2 25 | $174.4M | $206.0M | ||
| Q1 25 | $170.5M | $148.8M | ||
| Q4 24 | $186.5M | $188.3M | ||
| Q3 24 | $191.2M | $232.7M | ||
| Q2 24 | $182.4M | $176.0M | ||
| Q1 24 | $171.8M | $138.5M |
净利润AMPHMCS
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $16.2M | ||
| Q2 25 | $31.0M | $7.3M | ||
| Q1 25 | $25.3M | $-16.8M | ||
| Q4 24 | $38.0M | $986.0K | ||
| Q3 24 | $40.4M | $23.3M | ||
| Q2 24 | $37.9M | $-20.2M | ||
| Q1 24 | $43.2M | $-11.9M |
毛利率AMPHMCS
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
营业利润率AMPHMCS
| Q4 25 | 19.4% | 0.9% | ||
| Q3 25 | 13.2% | 10.8% | ||
| Q2 25 | 24.2% | 6.3% | ||
| Q1 25 | 21.9% | -13.7% | ||
| Q4 24 | 24.2% | -1.2% | ||
| Q3 24 | 29.8% | 14.1% | ||
| Q2 24 | 30.3% | 1.3% | ||
| Q1 24 | 27.9% | -12.0% |
净利率AMPHMCS
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | 7.7% | ||
| Q2 25 | 17.8% | 3.6% | ||
| Q1 25 | 14.8% | -11.3% | ||
| Q4 24 | 20.4% | 0.5% | ||
| Q3 24 | 21.1% | 10.0% | ||
| Q2 24 | 20.8% | -11.5% | ||
| Q1 24 | 25.1% | -8.6% |
每股收益（稀释后）AMPHMCS
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | — | ||
| Q2 25 | $0.64 | — | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.78 | — | ||
| Q2 24 | $0.73 | — | ||
| Q1 24 | $0.81 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $23.4M |
| 总债务越低越好 | $608.7M | $159.0M |
| 股东权益账面价值 | $788.8M | $457.4M |
| 总资产 | $1.6B | $1.0B |
| 负债/权益比越低杠杆越低 | 0.77× | 0.35× |
8季度趋势，按日历期对齐
现金及短期投资AMPHMCS
| Q4 25 | $282.8M | $23.4M | ||
| Q3 25 | $276.2M | $7.4M | ||
| Q2 25 | $231.8M | $14.9M | ||
| Q1 25 | $236.9M | $11.9M | ||
| Q4 24 | $221.6M | $40.8M | ||
| Q3 24 | $250.5M | $28.4M | ||
| Q2 24 | $217.8M | $32.8M | ||
| Q1 24 | $289.6M | $17.3M |
总债务AMPHMCS
| Q4 25 | $608.7M | $159.0M | ||
| Q3 25 | $608.6M | $162.0M | ||
| Q2 25 | $607.7M | $179.9M | ||
| Q1 25 | $603.9M | $198.9M | ||
| Q4 24 | $601.6M | $159.1M | ||
| Q3 24 | $596.4M | $173.1M | ||
| Q2 24 | $586.9M | $175.7M | ||
| Q1 24 | $594.0M | $169.8M |
股东权益AMPHMCS
| Q4 25 | $788.8M | $457.4M | ||
| Q3 25 | $776.7M | $454.3M | ||
| Q2 25 | $757.5M | $448.4M | ||
| Q1 25 | $751.3M | $441.8M | ||
| Q4 24 | $732.3M | $464.9M | ||
| Q3 24 | $727.7M | $462.3M | ||
| Q2 24 | $713.3M | $449.4M | ||
| Q1 24 | $672.4M | $459.3M |
总资产AMPHMCS
| Q4 25 | $1.6B | $1.0B | ||
| Q3 25 | $1.7B | $1.0B | ||
| Q2 25 | $1.6B | $1.0B | ||
| Q1 25 | $1.6B | $1.0B | ||
| Q4 24 | $1.6B | $1.0B | ||
| Q3 24 | $1.5B | $1.0B | ||
| Q2 24 | $1.5B | $1.1B | ||
| Q1 24 | $1.6B | $1.0B |
负债/权益比AMPHMCS
| Q4 25 | 0.77× | 0.35× | ||
| Q3 25 | 0.78× | 0.36× | ||
| Q2 25 | 0.80× | 0.40× | ||
| Q1 25 | 0.80× | 0.45× | ||
| Q4 24 | 0.82× | 0.34× | ||
| Q3 24 | 0.82× | 0.37× | ||
| Q2 24 | 0.82× | 0.39× | ||
| Q1 24 | 0.88× | 0.37× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $48.8M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $26.4M |
| 自由现金流率自由现金流/营收 | 13.4% | 13.6% |
| 资本支出强度资本支出/营收 | 4.5% | 11.6% |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | $989.0K |
8季度趋势，按日历期对齐
经营现金流AMPHMCS
| Q4 25 | $32.9M | $48.8M | ||
| Q3 25 | $52.6M | $39.1M | ||
| Q2 25 | $35.6M | $31.6M | ||
| Q1 25 | $35.1M | $-35.3M | ||
| Q4 24 | $29.0M | $52.6M | ||
| Q3 24 | $60.0M | $30.5M | ||
| Q2 24 | $69.1M | $36.0M | ||
| Q1 24 | $55.3M | $-15.1M |
自由现金流AMPHMCS
| Q4 25 | $24.6M | $26.4M | ||
| Q3 25 | $47.2M | $18.2M | ||
| Q2 25 | $25.0M | $14.7M | ||
| Q1 25 | $24.4M | $-58.3M | ||
| Q4 24 | $16.6M | $27.1M | ||
| Q3 24 | $46.2M | $12.0M | ||
| Q2 24 | $63.1M | $16.1M | ||
| Q1 24 | $46.5M | $-30.5M |
自由现金流率AMPHMCS
| Q4 25 | 13.4% | 13.6% | ||
| Q3 25 | 24.6% | 8.7% | ||
| Q2 25 | 14.3% | 7.1% | ||
| Q1 25 | 14.3% | -39.2% | ||
| Q4 24 | 8.9% | 14.4% | ||
| Q3 24 | 24.1% | 5.2% | ||
| Q2 24 | 34.6% | 9.2% | ||
| Q1 24 | 27.1% | -22.0% |
资本支出强度AMPHMCS
| Q4 25 | 4.5% | 11.6% | ||
| Q3 25 | 2.8% | 9.9% | ||
| Q2 25 | 6.1% | 8.2% | ||
| Q1 25 | 6.3% | 15.5% | ||
| Q4 24 | 6.7% | 13.5% | ||
| Q3 24 | 7.2% | 7.9% | ||
| Q2 24 | 3.3% | 11.3% | ||
| Q1 24 | 5.1% | 11.1% |
现金转化率AMPHMCS
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 2.41× | ||
| Q2 25 | 1.15× | 4.32× | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | 53.31× | ||
| Q3 24 | 1.48× | 1.31× | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
MCS
| Theatres | $123.1M | 64% |
| Concessions | $51.0M | 26% |
| Food And Beverage | $21.2M | 11% |
